Ownership Capital B.V. Sells 13,052 Shares of Insulet Co. (NASDAQ:PODD)

Ownership Capital B.V. cut its holdings in shares of Insulet Co. (NASDAQ:PODD) by 6.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 180,842 shares of the medical instruments supplier’s stock after selling 13,052 shares during the quarter. Insulet accounts for approximately 1.7% of Ownership Capital B.V.’s holdings, making the stock its 22nd biggest holding. Ownership Capital B.V.’s holdings in Insulet were worth $47,212,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Blue Trust Inc. raised its position in Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares during the period. Venturi Wealth Management LLC grew its holdings in shares of Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 133 shares during the last quarter. TD Private Client Wealth LLC increased its stake in shares of Insulet by 32.6% in the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after buying an additional 56 shares during the period. Friedenthal Financial bought a new stake in Insulet during the 4th quarter valued at $57,000. Finally, Versant Capital Management Inc boosted its position in Insulet by 106.1% during the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock valued at $80,000 after buying an additional 157 shares during the period.

Insider Transactions at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Analyst Upgrades and Downgrades

PODD has been the topic of a number of analyst reports. Citigroup boosted their price objective on shares of Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. TD Cowen boosted their price target on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a report on Friday, January 3rd. Morgan Stanley increased their price objective on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Canaccord Genuity Group upped their target price on Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a report on Monday, December 9th. Finally, Wells Fargo & Company raised their price target on Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $277.13.

Insulet Stock Performance

Insulet stock opened at $283.68 on Thursday. The stock’s 50 day moving average is $272.37 and its 200 day moving average is $246.18. The company has a market capitalization of $19.90 billion, a P/E ratio of 48.58, a PEG ratio of 3.52 and a beta of 1.23. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $289.46. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.